The creation of long-term memories requires a continual supply of myelin provided by newly formed oligodendrocytes. Alas, the generation of fresh oligodendrocytes diminishes with age, along with memory.
Researchers gain traction in the study of these rare tau disorders, which are sometimes confused with Alzheimer’s disease.
Vision improved in some retinitis pigmentosa patients in a Phase 1 trial.
Researchers at an international frontotemporal dementia congress reported progress in finding markers that track disease, but no luck thus far with diagnostic markers.
At CTAD, tau-PET data from people in different stages of various neurodegenerative diseases highlighted both commonalities and peculiarities.
Rather than changing one by one, many biomarkers—including cognition, tau PET, hippocampal atrophy, and CSF p-tau—shift together, around the time of symptom onset in young adults with familial AD.
New research presented at the HAI conference also finds links between UCB-J uptake and plaques, tangles, and cognitive decline.
Antisense Oligonucleotides: Can They Take on ALS, SMA, Prions? Drug Reported to Help Alzheimer’s Patients Sleep Better American Academy of Neurology 2019 Annual Meeting ...
Amyloid and tau PET are helping scientists pinpoint the underlying cause of specific AD symptoms. Perhaps imaging of certain brain regions will help predict an individual’s progression.
At HAI 2020, scientists more precisely quantified the relationship between plaques, tangles, and cognitive decline.
When observed over an eight-year period, people with the highest plasma concentrations were more likely to die than people with lower levels.
By engaging scientists studying every tau-based disorder, a new conference aimed to foster collaborations and research directions.
PET Tracer Detects Synapse Loss Across Alzheimer’s Brain Multimodal Imaging of Neurodegenerative Diseases Links Pathology and Cellular Dysfunction Tau PET: The Field Expands Rapidly Can PET Match Up Areas of Protein Deposit With Alzheimer’s Symptoms? How ...
At CTAD, a handful of candidate therapies were reported to have flamed out in Phase 2. They were unable to show efficacy. A new antipsychotic is entering the ring.
Tau2020: Meeting for Tauopathies Debuts Genetic Variants Behold the First Human α-Synuclein CryoEM Fibril Structure New at Tau2020: PET Detects First Traces of Tangles in Rhinal Cortex Primary Tauopathies Get New PET Ligands Tau Receptor Identified on ...